Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.12490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.
Inflammopharmacology
April 2024
Skin Repair Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Article Synopsis
- Prurigo nodularis (PN) is a skin disease characterized by severe itching, significantly impacting patients' quality of life, with certain cytokines like IL-31 and OSM playing key roles in its development.
- Two biologics, nemolizumab and vixarelimab, inhibit IL-31, with vixarelimab also targeting OSM, and this review assesses their effectiveness and safety for managing PN.
- Studies indicated that patients treated with nemolizumab experienced significant improvements in itch severity and quality of sleep compared to those on placebo, while vixarelimab demonstrated similar benefits in reducing itching and enhancing overall quality of life.
Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs.
Vet Immunol Immunopathol
April 2023
Zoetis Inc, 333 Portage Street, Kalamazoo, MI 49007, USA.
Lokivetmab (Cytopoint®, Zoetis) is a canine monoclonal antibody that specifically binds and neutralizes interleukin (IL)-31. Lokivetmab is approved for use in dogs for the treatment of atopic dermatitis (AD) and allergic dermatitis. The laboratory safety of lokivetmab was evaluated in 2 studies by adapting the science-based, case-by-case approach used for preclinical and early clinical safety evaluation of human biopharmaceuticals.
View Article and Find Full Text PDFNemolizumab: First Approval.
Drugs
July 2022
Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Article Synopsis
- Nemolizumab is a humanized monoclonal antibody targeting the IL-31 receptor, developed for treating various skin diseases like atopic dermatitis and chronic kidney disease-related itching.
- It works by blocking IL-31, a cytokine that contributes to itch and inflammation in skin conditions.
- The drug was approved in Japan in March 2022 for individuals aged 13 and older when other treatments fail to relieve itch associated with atopic dermatitis.
Nemolizumab for atopic dermatitis.
Drugs Today (Barc)
April 2022
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Article Synopsis
- * Nemolizumab is an IL-31 receptor antibody that has shown significant effectiveness in reducing itching and mild improvement in dermatitis during phase II and III clinical studies, with quick results.
- * While nemolizumab has some mild and temporary side effects, such as nasopharyngitis and increased AD symptoms, it is considered a promising treatment option for AD due to its efficacy and safety profile.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!